Alkem Laboratories Ltd Financials
Company Logo

Alkem Laboratories Ltd Financial Statement

Alkem Laboratories Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue2606.20
Operating Expense1879.47
Net Profit583.25
Net Profit Margin22.38
Earning Per Share48.78
EBIDTA780.30
Effective Tax Rate15.31

Alkem Laboratories Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual9,747.72
Operating Expenses Annual7,782.59
Operating Profit Annual2,207.29
Interest Annual81.91
Depreciation217.71
Net Profit Annual1,747.15
Tax Annual133.88

Alkem Laboratories Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning5.01
Cash Flow from Operations1,686.56
Cash Flow from Investing-865.60
Cash Flow from Financing-959.04
Cash Flow at the End-133.07

Alkem Laboratories Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)22.64
PBIT Margin (%)20.14
PBT Margin (%)19.89
Net PROFIT Margin (%)17.92
Return On Networth / Equity (%)17.56
Return On Networth /Employed (%)17.28
Return On Assets (%)15.41
Total Debt / Equity (X)0.11
Asset Turnover Ratio (%)0.86

Alkem Laboratories Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual1,823.09
Total Current Assets Annual8,040.08
Non Current Assets Annual5,997.72
Total Shareholders Funds Annual10,554.61
Total Assets Annual14,037.80

Alkem Laboratories Ltd Earning Calls

EPS (INR)

Expected

45.60

Reported

45.60

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by -0.04%

Sep 2023

EPS beaten by -0.02%

Get Your FAQs Right

As of Oct 15, 2024, Alkem Laboratories Ltd has a market capitalization of 59,067.50 Cr. Value Research classifies it as a Large-Cap company.
Yes, Alkem Laboratories Ltd is debt-free with a debt-to-equity ratio of 0.10.
In FY 2023 , Alkem Laboratories Ltd recorded a total revenue of approximately 9,747.72 Cr marking a significant milestone in the company's financial performance.
Alkem Laboratories Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.0% annually, respectively..
Alkem Laboratories Ltd's current PE ratio is 33.81.
Alkem Laboratories Ltd's ROCE averaged 15.5% from the FY ending March 2022 to 2024, with a median of 16.2%. It peaked at 16.8% in March 2024, reflecting strong capital efficiency over the period..
Alkem Laboratories Ltd's latest EBIT is Rs. 1,962.94 Cr, surpassing the average EBIT of Rs. 1,722.53 Cr over the 5 years..